赛诺菲的Dupixent成为日本十多年来首个新型COPD生物治疗药物. Sanofi's Dupixent becomes first new COPD biologic treatment approved in Japan in over a decade.

Sanofi's Dupixent已被日本批准为首例针对患有慢性阻塞性肺病(COPD)的成年人的生物治疗, Sanofi's Dupixent has been approved in Japan as the first biologic treatment for adults with chronic obstructive pulmonary disease (COPD) who have uncontrolled symptoms and elevated blood eosinophils. 批准所依据的研究显示,它能减少加重症并改进肺功能。 Approval is based on studies showing it reduces exacerbations and improves lung function. 慢性阻塞性肺病影响全球数百万人，导致持续咳嗽、粘液产生和呼吸困难，Dupixent 在日本十多年没有慢性阻塞性肺病后提供了一种新的治疗选择。 COPD affects millions globally, causing persistent cough, mucus production, and breathlessness, and Dupixent offers a new treatment option after over a decade without one in Japan.